Ruxolitinib Cream Outperforms Vehicle in Cutaneous Lichen Planus Trial

A phase 2, 16-week randomized, double-blind, vehicle-controlled trial with a 16-week open-label extension evaluated ruxolitinib 1.5% cream in 64 adults with cutaneous lichen planus across 19 US and Canadian sites. The trial reported that significantly more patients achieved IGA treatment success with ruxolitinib versus vehicle (50.0% vs 21.9%, P=.01) and greater itch improvement (48.4% vs 16.1%, P=.004) at week 16, with no serious treatment-emergent adverse events or discontinuations due to adverse events reported with ruxolitinib. The authors state the findings suggest ruxolitinib cream represents a potential treatment option for cutaneous lichen planus.

Most relevant for: Adults with predominantly cutaneous lichen planus affecting 20% or less body surface area with moderate-to-severe itch and disease severity.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.